Akashi Therapeutics Appoints Alka Batycky to Executive Vice-President, Portfolio Management and Operations
CAMBRIDGE, Mass., Dec. 1, 2016 /PRNewswire/ -- Akashi Therapeutics, a clinical stage biopharmaceutical company, announced the appointment of Alka Batycky, PhD as executive vice president, portfolio management and operations. Dr. Batycky will be responsible for directing the cross-functional development of the company's pipeline of three products targeting Duchenne muscular dystrophy and for overseeing corporate operations.
"Dr. Batycky brings a wealth of experience leading drug development programs as Akashi expands our focus from a single clinical program to active development of three different molecules," said Marc B. Blaustein, CEO. "We are pleased to welcome her to the Akashi team."
With more than 18 years of experience in the pharmaceutical industry, Dr. Batycky has held several senior level management positions, most recently at WARP Drive Bio and AMAG Pharmaceuticals. She has led functions including program and alliance management, clinical operations, and regulatory affairs. Previously, Dr. Batycky held positions of increasing responsibility at CombinatoRx, Synta Pharmaceuticals, Alkermes and GlaxoSmithKline.
About Akashi Therapeutics:Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy. Akashi was founded by leading patient organizations Charley's Fund and Nash Avery Foundation in collaboration with biotechnology industry veterans to impact a central problem in rare diseases: rapid therapy development. Akashi is developing a pipeline of therapies with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. For more information, please visit www.akashirx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/akashi-therapeutics-appoints-alka-batycky-to-executive-vice-president-portfolio-management-and-operations-300370655.html
SOURCE Akashi Therapeutics